The Highly Productive Thermothelomyces heterothallica C1 Expression System as a Host for Rapid Development of Influenza Vaccines
(1) Influenza viruses constantly change and evade prior immune responses, forcing seasonal re-vaccinations with updated vaccines. Current FDA-approved vaccine manufacturing technologies are too slow and/or expensive to quickly adapt to mid-season changes in the virus or to the emergence of pandemic strains. Therefore, cost-effective vaccine technologies that can quickly adapt to newly emerged strains are desirable. (2) The filamentous fungal host Thermothelomyces heterothallica C1 (C1, formerly Myceliophthora thermophila) offers a highly efficient and cost-effective alternative to reliably produce immunogens of vaccine quality at large scale. (3) We showed the utility of the C1 system expressing hemagglutinin (HA) and a HA fusion protein from different H1N1 influenza A virus strains. Mice vaccinated with the C1-derived HA proteins elicited anti-HA immune responses similar, or stronger than mice vaccinated with HA products derived from prototypical expression systems. A challenge study demonstrated that vaccinated mice were protected against the aggressive homologous viral challenge. (4) The C1 expression system is proposed as part of a set of protein expression systems for plug-and-play vaccine manufacturing platforms. Upon the emergence of pathogens of concern these platforms could serve as a quick solution for producing enough vaccines for immunizing the world population in a much shorter time and more affordably than is possible with current platforms.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:10 |
|---|---|
| Enthalten in: |
Vaccines - 10(2022), 2 vom: 20. Jan. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Keresztes, Gabor [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Filamentous fungi |
|---|
| Anmerkungen: |
Date Revised 01.03.2022 published: Electronic Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.3390/vaccines10020148 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM337461171 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM337461171 | ||
| 003 | DE-627 | ||
| 005 | 20231225234447.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3390/vaccines10020148 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1124.xml |
| 035 | |a (DE-627)NLM337461171 | ||
| 035 | |a (NLM)35214607 | ||
| 035 | |a (PII)148 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Keresztes, Gabor |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The Highly Productive Thermothelomyces heterothallica C1 Expression System as a Host for Rapid Development of Influenza Vaccines |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 01.03.2022 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a (1) Influenza viruses constantly change and evade prior immune responses, forcing seasonal re-vaccinations with updated vaccines. Current FDA-approved vaccine manufacturing technologies are too slow and/or expensive to quickly adapt to mid-season changes in the virus or to the emergence of pandemic strains. Therefore, cost-effective vaccine technologies that can quickly adapt to newly emerged strains are desirable. (2) The filamentous fungal host Thermothelomyces heterothallica C1 (C1, formerly Myceliophthora thermophila) offers a highly efficient and cost-effective alternative to reliably produce immunogens of vaccine quality at large scale. (3) We showed the utility of the C1 system expressing hemagglutinin (HA) and a HA fusion protein from different H1N1 influenza A virus strains. Mice vaccinated with the C1-derived HA proteins elicited anti-HA immune responses similar, or stronger than mice vaccinated with HA products derived from prototypical expression systems. A challenge study demonstrated that vaccinated mice were protected against the aggressive homologous viral challenge. (4) The C1 expression system is proposed as part of a set of protein expression systems for plug-and-play vaccine manufacturing platforms. Upon the emergence of pathogens of concern these platforms could serve as a quick solution for producing enough vaccines for immunizing the world population in a much shorter time and more affordably than is possible with current platforms | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Thermothelomyces heterothallica C1 | |
| 650 | 4 | |a filamentous fungi | |
| 650 | 4 | |a influenza vaccine | |
| 650 | 4 | |a recombinant protein expression | |
| 650 | 4 | |a targeted influenza hemagglutinin | |
| 650 | 4 | |a trimeric influenza hemagglutinin | |
| 700 | 1 | |a Baer, Mark |e verfasserin |4 aut | |
| 700 | 1 | |a Alfenito, Mark R |e verfasserin |4 aut | |
| 700 | 1 | |a Verwoerd, Theo C |e verfasserin |4 aut | |
| 700 | 1 | |a Kovalchuk, Andriy |e verfasserin |4 aut | |
| 700 | 1 | |a Wiebe, Marilyn G |e verfasserin |4 aut | |
| 700 | 1 | |a Andersen, Tor Kristian |e verfasserin |4 aut | |
| 700 | 1 | |a Saloheimo, Markku |e verfasserin |4 aut | |
| 700 | 1 | |a Tchelet, Ronen |e verfasserin |4 aut | |
| 700 | 1 | |a Kensinger, Richard |e verfasserin |4 aut | |
| 700 | 1 | |a Grødeland, Gunnveig |e verfasserin |4 aut | |
| 700 | 1 | |a Emalfarb, Mark |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Vaccines |d 2012 |g 10(2022), 2 vom: 20. Jan. |w (DE-627)NLM239212347 |x 2076-393X |7 nnns |
| 773 | 1 | 8 | |g volume:10 |g year:2022 |g number:2 |g day:20 |g month:01 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3390/vaccines10020148 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 10 |j 2022 |e 2 |b 20 |c 01 | ||